Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702416 | 0.86 | L3MBTL1 (0.68) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL2134693 | 0.84 | CACNA1I (0.59) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL2134672 | 0.84 | CACNA1I (0.59) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL13701755 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL31498883 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL13702303 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL4178518 | 0.83 | EPHX2 (0.73) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL13890832 | 0.83 | L3MBTL1 (0.68) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL2715748 | 0.82 | EPHX2 (0.52) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL20474664 | 0.81 | L3MBTL1 (0.70) | L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | L3MBTL1 3938/4885EPHX2 2/4885CYP2C9 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.